The trouble with Trump's homelessness plan
The Trump administration is pushing to involuntarily commit more people to psychiatric hospitals in an effort to keep them off the street, according to a new executive order issued Friday.
'Shifting homeless individuals into long-term institutional settings for humane treatment through the appropriate use of civil commitment will restore public order,' the memo states. It also calls for defunding 'housing first' programs, which prioritize quickly getting people into stable housing with fewer restrictions.
With the order, the new Trump administration is entering an ongoing debate over nationwide crises in mental healthcare and housing, and the intersection of the two. In recent years, even some blue states and cities like New York and San Francisco have moved to increase the use of involuntary treatment. Proponents of these policies say that people with severe mental illness are often too sick to accept help and can pose a threat to themselves or others when left untreated. Critics argue that these approaches are ineffective, costly, and in violation of patients' civil rights.
This story is part of 'Trump Two: Six Months In,' a Marshall Project series taking stock of the administration's efforts to reshape immigration enforcement and criminal justice.
Some housing advocates say the president's order is a deflection. 'Some people experiencing homelessness have mental illness,' said Jesse Rabinowitz of the National Homelessness Law Center. 'That's not the cause of homelessness. The cause of homelessness is that housing is too expensive. Institutionalizing folks doesn't treat the root cause of the problem.'
Standards for when someone is eligible for involuntary treatment vary state by state, and attorneys say much of Trump's order is beyond his authority. But the order could have an impact on the distribution of federal funding and gives support to cities and states looking to crack down on homeless encampments.
To better understand the potential impact of this directive, The Marshall Project spoke with Jennifer Mathis, Deputy Director of the Bazelon Center for Mental Health Law, which advocates against 'unnecessary institutionalization' and for increased voluntary mental health treatment in community settings instead. This conversation was edited for length and clarity.
Were you surprised by this move by the Trump administration?
There had been chatter for a while about this happening. It was somewhat consistent with the rhetoric the president has used over the years in his campaigns and while in office. I think it's entirely misguided.
It's unusual, at best, for the president to tell the Justice Department to actively seek to undermine established law rather than to enforce it. There is Supreme Court precedent on civil commitment. [The state cannot involuntarily commit someone who doesn't have mental illness and isn't a danger to themselves or others.] That's the law of the land. There is no legal support for what they are advocating. If there were, they would not need to try to overturn judicial precedents.
What makes it 'misguided,' in your opinion?
It is a little peculiar to suggest that the primary goal of this administration — when it comes to people with mental health disabilities — is not to help them in the community, but to focus on civilly committing them. And then what happens? Are they going to civilly commit them on a long-term basis? You can't commit your way out of a problem of not having sufficient community services. That's the root cause of many of the issues they are addressing in this executive order.
It seems like a very backward vision of a system that resembles the one we came from many years ago, and that we got away from because it was not only destroying lives — it was destroying budgets as well. It is very costly to keep people institutionalized. If you don't focus on creating the services that people need to avoid it, or to be discharged and free up other beds when people need them — you will continue to have people showing up at the front door. Civilly committing everybody doesn't solve that problem. You can't create hospitals ad nauseam. This is not serving people or treating them. It's warehousing.
How does this order square with research on reducing homelessness or the use of involuntary treatment?
These provisions about using discretionary grants to expand civil commitments and involuntary outpatient commitments, to stop supporting housing-first policies or harm reduction policies — all of that seems to signal a shift away from evidence-based practices. There is a mountain of evidence supporting housing-first, that it works, and that it's been a very effective and important strategy to meet the needs of people who often have the highest needs. Housing-first had bipartisan support for many, many years. It was started during the George W. Bush administration. That is a really effective strategy.
To say we're not going to house people who — by virtue of their situation or disability — are not going to be able to comply with certain requirements, and therefore we're going to leave them on the street, has not been very effective. So what will happen to the people who will remain unhoused? They're going to be civilly committed then? And then what? Hospitalization is not a magic pill. They don't seem to have a plan for what happens after.
On assisted outpatient treatment [the practice of providing someone with involuntary mental health or addiction treatment in the community under a court order], this executive order seems to be promoting it and suggesting agencies should use all means available to expand it. But the Government Accountability Office just issued a report saying evidence is inconclusive that assisted outpatient treatment actually does anything.
I don't think this has become a priority issue among most conservatives. I think there are particular groups for whom this has been a priority. It's not like Republicans broadly are clamoring for this.
There have been efforts to demonize people with mental health disabilities and portray them as violent, even despite a lack of evidence. All the data over all the years shows that people with mental illnesses account for 3 to 5% of violence. There was a specific effort to create these associations in the public mind of mental health and violence, because it was a convenient narrative. Some people did it because fear was a good way to generate support for mental health services, since otherwise, people didn't seem to care. There were other actors who had other motivations and were happy to take advantage of those increasing public fears to scapegoat people with mental health disabilities to divert from gun control conversations. Whether it's right or left, both have been guilty of perpetuating those stereotypes.
There has been a trend over the years to lower civil commitment standards. Apparently, the president thinks they should be [even] lower. Certain groups exist in states across the country who have beaten the drums for lowering [them]. It becomes a politicized issue where legislatures feel pressured to do something in the wake of a [violent] incident, and the answer is painted as 'if you just lowered civil commitment standards, then this wouldn't happen.'
What does it mean to issue this order just as Congress approved significant cuts to Medicaid and other social services?
That's the absurdity of it.
Hospitals are the most costly services we have in our system — that is why state mental health systems moved away from psychiatric hospitals. Also, because it was much better for people to live a life in the community.
We are in an era where Congress has made historic cuts to the Medicaid program, and states are going to face massive shortfalls in their mental health service systems. The idea of encouraging states to bypass interventions that would help people avoid hospitalization and to live in the community, and instead spending historically scarce resources on the most expensive interventions … seems completely flawed. They would be able to serve far fewer people. It makes no sense.
SUPPORT: YOU MAKE OUR WORK POSSIBLE
This article was first published by The Marshall Project, a nonprofit news organization covering the U.S. criminal justice system. Sign up for their newsletters, and follow them on Instagram, TikTok, Reddit and Facebook.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
The spice linked to low blood sugar and gum disease prevention
HOLD FOR PUB UNTIL FRI Cloves can do much more than just sweeten your baked goods. Used for thousands of years in traditional medicine, the warm spice commonly used in pumpkin pie and mulled wine may also benefit your gum health and lower your blood pressure, according to years of research. 'The antibacterial properties of cloves help kill harmful bacteria inside your mouth,' Idaho's Summit Dental Group explains. 'This makes cloves highly effective in controlling plaque and reducing the risk of gum disease.' Clove oil serves as a natural antimicrobial substance, stopping the growth of bacteria and fungi, according to studies. Just a few drops are enough. People shouldn't add more than 10 to 15 drops in an ounce of water, according to the National Association for Holistic Aromatherapy. Clove oil can be an irritant for some people, particularly on the skin. This is because cloves contain eugenol, a yellow-colored compound commonly found in cinnamon and bay leaves. Eugenol affects the our ability to stop bleeding, according to the Cleveland Clinic. It can be harmful when adults take as little as 10 milliliters of eugenol, according to Mount Sinai. Children should not consume it. Still, eugenol is generally safe in the quantities found in food products made with ground cloves. Most pumpkin pie recipes don't call for more than a teaspoon of the spice. Eugenol has the ability to kill yeast, which can be the result of an overgrowth of fungus in the mouth. The compound is also what researchers say can lower your blood sugar levels. After taking 250 milligrams of clove extract daily for 30 days, researchers said participants in a 2019 study had significantly lower blood sugar after meals. Cloves are also packed with essential minerals. The spice has calcium to maintain strong bones, magnesium that can regulate blood sugar and calcium levels, potassium that helps the nerves and supports heart health, and vitamin K, which helps keep arteries healthy. Eugenol may help improve bone mass as well, according to research on animals. Lastly, cloves are a natural antioxidant, the substances found in foods that can prevent damage to cells and DNA. Experts say people need a variety of antioxidant-rich foods each day, such as berries and nuts. 'Antioxidants are almost like a shield around your cells, like a blanket around them to protect them from oxidative damage,' registered dietitian Julia Zumpano explained to the Cleveland Clinic.
Yahoo
23 minutes ago
- Yahoo
Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Epigenetics Market, valued at US$2.03 billion in 2024, stood at US$2.24 billion in 2025 and is projected to advance at a resilient CAGR of 13.9% from 2025 to 2030, culminating in a forecasted valuation of US$4.29 billion by the end of the period. The major factors driving the growth in the flow cytometry market include advancements in technology, increasing adoption of flow cytometry products in clinical diagnostics, rising prevalence of chronic diseases, growing biopharmaceutical R&D, and the need for precision medicine. The significant rise in oncology research has increased the demand for flow cytometry products and services. Additionally, the integration of AI and machine learning is enhancing data analysis capabilities, further fueling market growth. Download PDF Brochure: Browse in-depth TOC on "Epigenetics Market" 365 - Tables45 - Figures353 - Pages By offering, the global epigenetics market is segmented into various categories, including kits and reagents, enzymes, instruments and accessories, software, and services. Within the kits and reagents category, there are sub-segments such as antibodies, chip-sequencing kits and reagents, bisulfite conversion kits and reagents, whole-genome amplification kits and reagents, 5-HMC and 5-MC analysis kits and reagents, histones, as well as other kits and reagents. In 2024, the Antibodies segment is projected to command the largest market share. This is attributed to the increasing reliance on antibodies for the detection, identification, and modification of proteins, along with their essential function in monitoring cellular regulation and gene expression. Consequently, the growth of the antibodies segment is expected to accelerate throughout the forecast period due to these advancements. By Method, the epigenetics market segmentation by methodology includes DNA methylation, histone modifications, and additional approaches such as non-coding RNA interactions and chromatin remodeling. The DNA methylation segment is projected to exhibit a robust compound annual growth rate (CAGR) throughout the forecast period, primarily driven by its proven effectiveness in oncology research applications. By geography, The Asia Pacific region is projected to experience the most rapid growth within the epigenetics market. This expansion is driven by the increasing global footprint of local companies through strategic alliances and collaborations, alongside continuous enhancements in healthcare infrastructure in emerging economies. Moreover, there is a heightened emphasis on advancing capabilities in Next-Generation Sequencing (NGS), which is further propelling market development in the region. Request Sample Pages : Key players in the epigenetics market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher (US), Active Motif, Inc. (US), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Revvity (US), QIAGEN (Germany), among others. Illumina Inc (US): In 2024, Illumina, Inc. maintained a preeminent position in the genomics market, capitalizing on a well-established customer base that includes leading pharmaceutical and biotechnology companies, genomic research institutions, and various government laboratories and hospitals. The firm possesses a dominant market share in the next-generation sequencing (NGS) domain, which affords it a competitive edge when exploring adjacent sectors, such as epigenetic sequencing. A notable move in this direction occurred in June 2025, when Illumina announced its acquisition of SomaLogic. This strategic acquisition is poised to bolster Illumina's footprint in the burgeoning epigenetics market and further its multiomics strategy, integrating diverse biological data for enhanced insights into genomics, transcriptomics, proteomics, and epigenomics. Thermofisher Scientific Inc. (US) Thermo Fisher Scientific Inc. (US) stands out as a prominent player in the epigenetics market in 2024, driven by a robust and diversified product portfolio, an extensive global footprint, and a strategic focus on both organic and inorganic growth initiatives. Notably, in July 2025, the company secured US Food and Drug Administration (FDA) approval for the Oncomine Dx Express Test, utilizing the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay designed for companion diagnostics (CDx) in tumor profiling applications. Thermo Fisher demonstrates a strong commitment to research and development, channeling significant resources into innovation to address the dynamic needs of its clientele. Their comprehensive global distribution network enhances accessibility and customer support, facilitating the delivery of advanced and reliable epigenetics solutions. This multifaceted strategic approach solidifies Thermo Fisher's position as a leading provider in the epigenetics landscape. For more information, Inquire Now! Related Reports: Research Antibodies & Reagents Market Genomics Market Next Generation Sequencing Market PCR Technologies Market Digital PCR and qPCR Market Get access to the latest updates on Epigenetics Companies and Epigenetics Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Trump officials wanted to give Musk's xAI a huge contract. Staffers had to explain Grok had just praised Hitler
Donald Trump's administration was close to giving Elon Musk's xAI artificial intelligence company a huge federal contract this summer, only to back out after its chatbot, Grok, began issuing antisemitic slurs, according to a report. According to Wired, emails between several AI developers and the General Services Administration, which is responsible for administering government tech contracts, chart how the proposed partnership fell apart as Musk's pet project began dabbling in Nazi rhetoric. In early June, around the time the president and the tech billionaire suffered a spectacular public falling out, exchanging barbed personal insults over their competing social media platforms, the GSA's leadership was meeting with the xAI team 'to see what opportunities may exist for automation and streamlining,' according to the outlet. Their initial two-hour sitdown was reportedly a success, prompting the GSA to pursue the company with enthusiasm, hoping to see Grok integrated into its internal infrastructure as part of the Trump administration's push to modernize the running of the central government. 'We kept saying, 'Are you sure?' And they were like 'No, we gotta have Grok,'' one employee involved in the discussions told Wired. The conversations continued over the following weeks, and xAI was eventually added to the GSA Multiple Award Schedule, the agency's government-wide contracting program. Then, in early July, Grok suddenly went haywire after an update to make it less 'woke' than its competitors went too far, leading to the chatbot referring to itself as 'MechaHitler' in homage to the robotic version of Adolf Hitler that appeared in the 1992 video game Wolfenstein 3D. Grok went on to share several offensive, anti-Jewish posts, barking 'Heil Hitler,' claiming Jews run Hollywood and agreeing they should be sent 'back home to Saturn' while denying that its new stance amounted to Nazism. 'Labeling truths as hate speech stifles discussion,' it declared. Musk's company apologized for the upset and scrubbed the 'inappropriate' posts. Still, it was not seemingly enough to save xAI's relationship with the GSA, although the furore was allegedly not noticed, at least initially, by the agency's leadership. 'The week after Grok went MechaHitler, [the GSA's management] was like 'Where are we on Grok?'' the same employee told Wired. 'We were like, 'Do you not read a newspaper?'' When the U.S. government duly announced a series of partnerships with the likes of OpenAI, Anthropic, Google Gemini, and Box, an AI-based content management platform, in early August, xAI's name was not among them. The GSA has not definitively stated that Grok's outburst was the reason for the scrapping of xAI's proposed contract, but two company employees told Wired they believed that was the case. The Independent has reached out to the GSA for more information. The GSA's talks with the AI firms coincided with Trump's administration publishing its AI Action Plan in July, which laid out its goals for the United States to become a world leader in the emerging sector while calling for a reduction in regulation and red tape. Solve the daily Crossword